Roche Holding AG ASH Virtual Update Event Transcript
Kindly note that the webinar is being recorded. (Operator Instructions) One last remark. If you would like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the presentation.
At this time, it's my pleasure to introduce you to Karl Mahler, Head of Investor Relations and Group Planning. Karl, the stage is yours.
Yes. Thanks a lot, Henrik, for the kind introduction. Welcome to our ASH science call today. This is the last one for this year. It's close to Christmas, and this is also a testimony of the good science, which we had in the past year, I think, on various occasions.
So very excited to present an update on the probably largest and broadest hematology pipeline in the industry. And maybe from my side, to highlight definitely 2 things, there's a lot of things you'll hear today, but maybe 2 things. One is the Phase II for our bispecifics in mosunetuzumab and glofitamab, which got an oral presentation here. And one other highlight definitely
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
